Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael L Goris

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 23, 2013
Prognostic utility of 90Y radioembolization dosimetry based on fusion 99mTc-macroaggregated albumin-99mTc-sulfur colloid SPECTMarnix G E H Lam, Michael L Goris, Andrei H Iagaru, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 29, 2015
Fusion dual-tracer SPECT-based hepatic dosimetry predicts outcome after radioembolization for a wide range of tumour cell typesMarnix G E H Lam, Arjun Banerjee, Michael L Goris, et al.
Journal of Vascular and Interventional Radiology : JVIR|April 7, 2009
Incorporating cone-beam CT into the treatment planning for yttrium-90 radioembolizationJohn D Louie, Nishita Kothary, William T Kuo, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 16, 2006
99mTc-HYNIC-annexin V SPECT imaging of acute stroke and its response to neuroprotective therapy with anti-Fas ligand antibodyFrancis G Blankenberg, Judy Kalinyak, Liping Liu, et al.
Radiology|April 20, 2011
Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: a PET radiopharmaceutical agent for imaging α(v)β(3) integrin levelsErik S Mittra, Michael L Goris, Andrei H Iagaru, et al.
Molecular Genetics and Metabolism|October 23, 2012
Brain uptake of Tc99m-HMPAO correlates with clinical response to the novel redox modulating agent EPI-743 in patients with mitochondrial diseaseFrancis G Blankenberg, Stephen L Kinsman, Bruce H Cohen, et al.
Cancer Biotherapy & Radiopharmaceuticals|August 22, 2006
Phase I study of 131I-chimeric(ch) TNT-1/B monoclonal antibody for the treatment of advanced colon cancerHilary Hardy Street, Michael L Goris, George Albert Fisher, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|October 25, 2002
Therapeutic lymphangiogenesis with human recombinant VEGF-CAndrzej Szuba, Mihaela Skobe, Marika J Karkkainen, et al.
Pediatric Pulmonology|January 22, 2020
Mucus plugging, air trapping, and bronchiectasis are important outcome measures in assessing progressive childhood cystic fibrosis lung diseaseTerry E Robinson, Michael L Goris, Richard B Moss, et al.
Blood|March 5, 2004
Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphomaAndres Forero, Paul L Weiden, Julie M Vose, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 23, 2013
Prognostic utility of 90Y radioembolization dosimetry based on fusion 99mTc-macroaggregated albumin-99mTc-sulfur colloid SPECTMarnix G E H Lam, Michael L Goris, Andrei H Iagaru, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 29, 2015
Fusion dual-tracer SPECT-based hepatic dosimetry predicts outcome after radioembolization for a wide range of tumour cell typesMarnix G E H Lam, Arjun Banerjee, Michael L Goris, et al.
Journal of Vascular and Interventional Radiology : JVIR|April 7, 2009
Incorporating cone-beam CT into the treatment planning for yttrium-90 radioembolizationJohn D Louie, Nishita Kothary, William T Kuo, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 16, 2006
99mTc-HYNIC-annexin V SPECT imaging of acute stroke and its response to neuroprotective therapy with anti-Fas ligand antibodyFrancis G Blankenberg, Judy Kalinyak, Liping Liu, et al.
Radiology|April 20, 2011
Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: a PET radiopharmaceutical agent for imaging α(v)β(3) integrin levelsErik S Mittra, Michael L Goris, Andrei H Iagaru, et al.
Molecular Genetics and Metabolism|October 23, 2012
Brain uptake of Tc99m-HMPAO correlates with clinical response to the novel redox modulating agent EPI-743 in patients with mitochondrial diseaseFrancis G Blankenberg, Stephen L Kinsman, Bruce H Cohen, et al.
Cancer Biotherapy & Radiopharmaceuticals|August 22, 2006
Phase I study of 131I-chimeric(ch) TNT-1/B monoclonal antibody for the treatment of advanced colon cancerHilary Hardy Street, Michael L Goris, George Albert Fisher, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|October 25, 2002
Therapeutic lymphangiogenesis with human recombinant VEGF-CAndrzej Szuba, Mihaela Skobe, Marika J Karkkainen, et al.
Pediatric Pulmonology|January 22, 2020
Mucus plugging, air trapping, and bronchiectasis are important outcome measures in assessing progressive childhood cystic fibrosis lung diseaseTerry E Robinson, Michael L Goris, Richard B Moss, et al.
Blood|March 5, 2004
Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphomaAndres Forero, Paul L Weiden, Julie M Vose, et al.
Pageof 3